Ancilia Biosciences’ Post

InVitria, Inc. is attending #ASGCT24 in Baltimore! We will be located at Booth 131. Stop by to learn how our sustainable recombinant technology has been implemented by #celltherapy and #genetherapy developers to enhance biomanufacturing and final formulation! Connect with us through the event meeting portal to schedule a meeting. Team Members attending include: Andrew Hamann, PhD, Mark Stathos, Ph.D., Jake Hanks, Marcus Curl, Elliott Renft, Colin Odishoo, and Scott Deeter. Here's how InVitria's innovations contribute to success: Sustainability A steadfast focus on reducing the environmental impact and ensuring a sustainable and ethical supply of critical components for clinical applications. Safety and Quality Our commitment to animal-free components significantly reduces the risk of contaminants and ensures higher manufacturing consistency. Performance Enhanced cell growth, productivity, and product yield, facilitating faster and more efficient production cycles. We believe these solutions are pivotal to a future where cell and gene therapy achieve their promise for patients. They are not just a step towards more ethical and sustainable practices but also a leap towards more reliable and efficient therapeutic production. #SustainableSolutions #CellTherapies #GeneTherapies #AnimalFree #CharmCity

The 42nd J.P. Morgan annual healthcare conference is well underway in California, hopefully the weather picks up this year! I'm looking forwarding to watch the keynotes, review the panels, and hear feedback on the exciting innovations presented by both established and new companies. This had me thinking, how would I pitch to investors at J.P. Morgan? To make a strong impression at J.P. Morgan, it's important to remember that simply being "better" than the competition isn't enough. You need to showcase how your company or product is fundamentally unique and different. It's all about standing out from the crowd! Bristol Myers Squibb and their new CEO, Chris Boerner caught my attention yesterday with their AI and machine learning to improve R&D at every step - from discovering novel disease targets to accelerating clinical trials - ultimately to provide the best outcome for patients. Some other notable well-established companies I'm looking forward to review include Amgen, Gilead Sciences and Moderna known for their groundbreaking therapies and innovative research. Additionally, there will be emerging biotech's like CRISPR Therapeutics, bluebird bio, Intellia Therapeutics, Inc. and Allogene Therapeutics who are pushing the boundaries of gene editing, Immunotherapies and personalised medicine. The biotech industry is buzzing with innovation. At Jackson Hogg, we're proud to keep collaborating with both our current partners and new organisations that are at the forefront of scientific advancements. We're excited to share our insights in the healthcare market and continue making a positive impact together! Who has caught your attention at the conference this year? #jpm2024 #jpmorgan #biotech #pharma #meddevice #biotechconference #2024success #2024planning #2024strategy #JacksonHogg #HeadHunting

🔬 Webinar Reminder! Revolutionize Your Single Cell Research with Scale Bio! 🧬 Are you tired of the limitations in single cell studies? Join our upcoming webinar to discover how Scale Bio is transforming the landscape of single cell experiments! Learn how to: •Scale projects to millions of cells without compromising quality •Multiplex 100s of samples per experiment with Scaleplex technology •Get 3x more cells within your current budget Perfect for researchers in: Single cell atlasing Drug discovery CRISPR genome-wide screens Large patient cohort studies Don't miss this opportunity to complete your large-scale projects in days, not months! Register now and unlock the power of affordable, high-throughput single cell analysis! https://hubs.la/Q02TkP5X0 #SingleCell #Genomics #Biotechnology #ResearchInnovation

A list of 10 clinical trial readouts to watch that could either stall or speed recent biotech momentum.#clinicaltrials #drugdevelopment #drugdiscovery

Understanding the benefit-risk ratio is a complex exercise for #genetherapies, where there hasn't been sufficient time to understand the long-term risks. How should we approach it? Tome Biosciences' Jonathan (John) Finn explains. https://lnkd.in/egJGZ4X6

#Cytiva & #LevitasBio team up for streamlined #singlecell workflow: Combining Cytiva's Via Extractor (tissue dissociation) with LevitasBio's LeviCell (isolation & #enrichment solution), to offer a new, #automated solution for single-cell #genomics research. https://shorturl.at/jtHKP

Our researchers utilize vast multi-omics datasets from both public and private sources to advance disease research, diagnostics, and treatment development. These resources are invaluable in exploring the drug discovery landscape. 📊🌐 Learn more about what we’re doing! 👇 https://lnkd.in/dEDuFUmP #Bioinformatics #OmicsData #DrugDevelopment #Delta4 #TechBio

The latest on #CRISPR technology from #Collison2024 ✨✨✨✨✨✨✨ Check out the video ✨✨✨✨✨✨✨✨

CatSci Ltd are thrilled to share that we have won a Llywodraeth Cymru Economi | Welsh Government Economy SMART Capital Equipment Fund grant to enhance our oligonucleotides capability and offer more and better R&D and manufacturing solutions to customers.  The grant will enable CatSci to invest in new cutting-edge equipment that will dramatically increase the rapid creation of a large pool of candidates of RNA/DNA sequences. This is critical for the identification of new therapies to address previously untreatable diseases. If you want to discuss how you can leverage our expert Oligos capabilities, we will be at RNA Leaders Europe, Basel (13th – 14th March) and TIDES USA, Boston (14th – 17th May). Read more here: https://lnkd.in/eduUt3pU    #ExcellenceInMedicinesDevelopment #Oligonucleotides #Innovation #MedicinesDevelopment #Oligos #RNATherapeutics #InnovationInMedicinesDevelopment #ChooseCatSci #RNALeaders #TIDESUSA

Our Chief Technology Officer Manmohan Singh, PhD, FAAPS, will be taking the stage as a panelist during the plenary keynote at this year's Bioprocessing Summit on August 21. He’ll join other industry leaders in a fireside chat to discuss the transformative potential of genetic medicines, including the technologies, tools and strategies to succeed in the clinic and commercially. Learn more about the conference here: https://lnkd.in/eqYsS33 #CHIBioprocessingSummit